Mittal, Abhenil
Al-Ezzi, Esmail
Li, Xuan
Moloney, Brian
Wilson, Brooke
Spiliopoulou, Pavlina http://orcid.org/0000-0002-6486-6319
Sridhar, Srikala
Fallah-Rad, Nazanin
Chung, Peter
Hamilton, Robert James
O’malley, Martin
Hansen, Aaron R. http://orcid.org/0000-0002-2363-8707
Article History
Received: 10 August 2022
Revised: 10 January 2023
Accepted: 16 January 2023
First Online: 1 March 2023
Competing interests
: There are no conflicts of interest pertaining to the contents of this manuscript. Other relationships are detailed: Dr. SS plays an advisory role for Astellas Pharma, Astrazeneca, Bayer, Bristol Mayers Squibb, Immunomedics, Janssen, Merck, Pfizer, Roche, Sanofi and Seattle Genetics. Dr. PC received honoraria from Abbvie, AstraZeneca and Boston Scientific, research funding from Abbvie and does consulting for Tersera and Verity Pharmaceuticals. Dr. RJH received honoraria from Abbvie, Astellas Pharma, Bayer and Janssen, research funding from Bayer and Janssen and travel/accommodation/expenses from Janssen. Dr. ARH does consulting for AstraZeneca, BMS, Eisai, GSK, Merck and Novartis. He has received research funding from Astellas Pharma, Astrazeneca, BionTech, Boehringer Ingelheim, BMS, GSK, Janssen, Karyopharm therapeutics, Merck, Neoleukin therapeutics, Pfizer/EMD Serono and Roche. Other authors have no relationships to disclose.
: UHN research ethics board approved the study (CAPCR ID- 17–6284).
: Not applicable.